Inauguration of MRI Facility and Health Service Initiative at Bhayangkara Kediri Hospital, Featuring DNA Testing Services in Collaboration with Regene Genomics

JAKARTA and KEDIRI, Indonesia, Dec. 24, 2024 /PRNewswire/ -- Bhayangkara Kediri Hospital inaugurated its new MRI service building and laid the cornerstone for a new service facility, marking a significant step forward in enhancing healthcare services in Kediri and surrounding areas.

The festive inauguration ceremony was led by Head of the Central Police Hospital, Police Brigadier General dr. Prima Heru Y, M.Kes., M.H., accompanied by the East Java Regional Police Medical and Health Central Team. The event, held at Bhayangkara Kediri Hospital, Jl. Kombes Duryat No. 17, Kediri City, was attended by several prominent figures, including Deputy Chief of the Kediri Resort Police Police Commissioner Dodik Tri Hendro S, S.H., S.I.K., M.I.K., Acting Mayor of Kediri represented by City Secretary Bagus Alit, and Chairman of PCNU Kediri City KH Abubakar Abdul Djalil (Gus AB).

In his speech, dr. Prima Heru stated that Bhayangkara Kediri Hospital is progressing rapidly with the addition of services such as the 3 Tesla MRI, DNA testing, executive polyclinic, aesthetic polyclinic, cardiac catheterisation, and more. The hospital aims to become a one-stop service facility so police personnel and the general public no longer need referrals to other hospitals. He expressed his hope that Bhayangkara Kediri Hospital will continue to grow and succeed.

One of the key moments of the inauguration was the announcement of a strategic collaboration between Bhayangkara Kediri Hospital and Regene Genomics, the most comprehensive DNA testing service provider in Indonesia, developed by local talent.

This collaboration aims to provide DNA and genomic testing services that can enhance lifestyles, improve diagnostic accuracy, support health planning, and aid in disease prevention for individuals, aligned with precision medicine. During the event, several attending officials personally tried Regene Genomics' DNA testing services as a symbolic gesture to mark the start of this collaboration.

The Head of Bhayangkara Kediri Hospital, Police Commissioner drg. Agung Hadi Wijanarko, Sp.BM, stated, "This collaboration is a significant step forward in delivering advanced, technology-based healthcare services to the community. With the new building facility and support from Regene Genomics, we are optimistic about providing more personalized and targeted healthcare solutions."

Regene Genomics is a DNA and genomic testing service provider developed by Indonesian talent, and recognized as the most comprehensive in Indonesia. Leveraging the latest Microarray Illumina technology, Regene offers a variety of benefits, including:

"Regene Genomics is proud to be part of the healthcare transformation at Bhayangkara Kediri Hospital. We believe DNA testing will become a vital solution in providing more personalized healthcare services," said the Chief Scientific Officer of Regene Genomics, Police Commissioner (Ret.) Drs. Putut Tjahjo Widodo, DFM, M.Si.

The inauguration of this new building and the collaboration with Regene Genomics demonstrate Bhayangkara Kediri Hospital's commitment to continuous innovation in delivering top-quality healthcare services to the general public. This step is expected to inspire other healthcare institutions to adopt genomic services to improve the health and quality of life of the Indonesian population.

Contact detail RS Bhayangkara:
Rumah Sakit Bhayangkara Kediri
Jl. Kombes Pol Duryat No.17, Dandangan, Kec. Kota, Kota Kediri, Jawa Timur 64122
Telepon: (0354) 671100

Contact detail Regene Genomics:
Regene Genomics (PT. Regene Artifisial Intelijen)
Blok TB No.35, Jl. Metro Pondok Indah, Pd. Pinang, Kec. Kby. Lama, Jakarta, Daerah Khusus Ibukota Jakarta 12310
Telepon: 0851-8682-3500, Website:  regene.ai 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Inauguration of MRI Facility and Health Service Initiative at Bhayangkara Kediri Hospital, Featuring DNA Testing Services in Collaboration with Regene Genomics

TOKYO, Dec. 25, 2024 /PRNewswire/ -- Kaneka has successfully defended its patent for stabilizing Ubiquinol. On December 20, 2024, Kaneka Corporation won its lawsuit against Designs for Health, Inc. and American River Nutrition, LLC for infringement of Kaneka's U.S. Patent No. 7,829,080 (the "'080 Patent"). The '080 Patent teaches a method of stabilizing ubiquinol against oxidation with a specific composition of chemical compounds. Ubiquinol is the reduced form of the health supplement coenzyme Q10, a powerful antioxidant that promotes cellular energy and heart health, which is more absorbable by the body than its oxidized form. Kaneka commenced its patent infringement action against defendants in 2021 in the United States District Court for the District of Delaware. 

Senior Judge William Bryson of the Federal Circuit, sitting by designation in the District Court, found that Design For Health, Inc.'s products, CoQNOL and Q10.1, which contain a formulation of ubiquinol known as DuoQuinol, infringe Kaneka's '080 Patent.  Judge Bryson also rejected defendants' arguments that the '080 Patent was invalid under Section 101 for lack of patent-eligible subject matter, Section 102 for anticipation, Section 103 for obviousness, and Section 112 for lack of written description. Judge Bryson will determine the amount of Kaneka's monetary damages next year.

"We are pleased that Judge Bryson has vindicated Kaneka's position that the '080 Patent was both infringed and valid" said Mr. Kazuhiko Fujii, President of Kaneka.  "This victory is tangible proof of Kaneka's resolve to fully enforce its patent rights, including its patents covering ubiquinol. The protection of Kaneka's patent rights is paramount to Kaneka's business. Kaneka's commitment to protecting these rights is unwavering."

Case Number: C.A. No. 21-209-WCB

Contact info: Ron Martin, Vice President, Kaneka North America - ronald.martin@kaneka.com

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Designs For Health Inc. Held Liable For Infringement of Kaneka's Ubiquinol Patent